Trials / Completed
CompletedNCT00458016
Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes Mellitus
A Phase 2, 28-day, Multicenter, Double-Blind,Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of MB07803 in Patients With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 105 (actual)
- Sponsor
- Ligand Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to collect important information regarding the safety, tolerability, and efficacy of MB07803 when administered for 28 days in patients with type 2 diabetes mellitus
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MB07803 | Daily oral administration |
| DRUG | Placebo | Daily oral administration |
Timeline
- Start date
- 2007-03-01
- Primary completion
- 2008-03-01
- Completion
- 2008-03-01
- First posted
- 2007-04-09
- Last updated
- 2011-10-03
Locations
25 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00458016. Inclusion in this directory is not an endorsement.